15 kg | 1.5 ml | 3 ml | 4.5 ml | 6 ml | 7.5 ml | 9 ml |
20 kg | 2 ml | 4 ml | 6 ml | 8 ml | 10 ml | 12 ml |
25 kg | 2.5 ml | 5 ml | 7.5 ml | 10 ml | 12.5 ml | 15 ml |
30 kg | 3 ml | 6 ml | 9 ml | 12 ml | 15 ml | 18 ml |
35 kg | 3.5 ml | 7 ml | 10.5 ml | 14 ml | 17.5 ml | 21 ml |
To be used twice a day, for adolescents and childrenwho weigh from 40 kg to less than 50 kg:
Weight | Week 1 Initial dose: 0.1 ml/kg | Week 2 0.2 ml/kg | Week 3 0.3 ml/kg | Week 4 0.4 ml/kg | Week 5 Maximum recommended dose: 0.5 ml/kg |
40 kg | 4 ml | 8 ml | 12 ml | 16 ml | 20 ml |
45 kg | 4.5 ml | 9 ml | 13.5 ml | 18 ml | 22.5 ml |
When using lacosamida with other antiepileptic medications
To be used twice a day,for children from 2 years of age whoweigh from 10 kg to less than 20 kg
Weight | Week 1 Initial dose: 0.1 ml/kg | Week 2 0.2 ml/kg | Week 3 0.3 ml/kg | Week 4 0.4 ml/kg | Week 5 0.5 ml/kg | Week 6 Maximum recommended dose: 0.6 ml/kg |
10 kg | 1 ml | 2 ml | 3 ml | 4 ml | 5 ml | 6 ml |
15 kg | 1.5 ml | 3 ml | 4.5 ml | 6 ml | 7.5 ml | 9 ml |
To be used twice a day, for adolescents and childrenwho weigh from 20 kg to less than 30 kg:
Weight | Week 1 Initial dose: 0.1 ml/kg | Week 2 0.2 ml/kg | Week 3 0.3 ml/kg | Week 4 Maximum recommended dose: 0.4 ml/kg |
20 kg | 2 ml | 4 ml | 6 ml | 8 ml |
25 kg | 2.5 ml | 5 ml | 7.5 ml | 10 ml |
To be used twice a day,for adolescents and childrenwho weigh from 30 kg to less than 50 kg
Weight | Week 1 Initial dose: 0.1 ml/kg | Week 2 0.2 ml/kg | Week 3 0.3 ml/kg | Week 4 Maximum recommended dose: 0.4 ml/kg |
30 kg | 3 ml | 6 ml | 9 ml | 12 ml |
35 kg | 3.5 ml | 7 ml | 10.5 ml | 14 ml |
40 kg | 4 ml | 8 ml | 12 ml | 16 ml |
45 kg | 4.5 ml | 9 ml | 13.5 ml | 18 ml |
If you interrupt treatment with Lacosamida Vivanta
If your doctor decides to stop your treatment with lacosamida, they will gradually reduce your dose. This is to prevent your epilepsy from recurring or worsening.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Side effects in the nervous system, such as dizziness, may be more pronounced after a single dose of "loading".
“de carga”.
Inform your doctor or pharmacist if you experience any of the following side effects:
Very common:may affect more than 1 in 10 patients
Common:may affect up to 1 in 10 patients
Uncommon:may affect up to 1 in 100 patients
Unknown frequency:cannot be estimated from available data
Other adverse effects of intravenous administration
Local adverse reactions may occur.
Common:may affect up to 1 in 10 patients
Uncommon:may affect up to 1 in 100 patients
Other adverse effects in children
Additional adverse effects observed in children were fever (pyrexia), runny nose (nasopharyngitis), sore throat (pharyngitis), eating less than usual (decreased appetite), changes in behavior, not acting normally (abnormal behavior), and lack of energy (lethargy). Drowsiness (somnolence) is a very common side effect in children and may affect more than 1 in 10 children.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and vial after CAD. The expiration date is the last day of the month indicated.
This medication does not require special conditions for conservation.
Each vial of Lacosamida Vivanta infusion solution must be used only once (single use). Unused solution must be discarded.
Only clear solutions, free of particles and without color change should be used.
Medications should not be thrown into the drains or trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.
Composition of Lacosamida Vivanta
1 ml of infusion solution contains 10 mg of lacosamida.
1 vial contains 20 ml of infusion solution, equivalent to 200 mg of lacosamida.
Appearance of the product and contents of the package
Lacosamida Vivanta 10 mg/ml infusion solution is a transparent and colorless solution.
Lacosamida Vivanta infusion solution is available in packages of 1 vial and 5 vials. Each vial contains 20 ml.
Only some package sizes may be marketed.
Marketing Authorization Holder
Vivanta Generics s.r.o.
Trtinová 260/1, Cakovice
196 00 Prague 9,
Czech Republic
Responsible for manufacturing
Pharmadox Healthcare Limited
KW20A Kordin Industrial Park, Paola, PLA3000, Malta
Ó
MSN Labs Europe Limited
KW20A Corradino Park, Paola, PLA3000, Malta
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Local Representative:
Vivanta Generics s.r.o. subsidiary in Spain
C/Guzmán el Bueno, 133, edificio Britannia
28003 Madrid
This medication is authorized in the member states of the European Economic Area with the following names:
Germany:Lacosamid Vivanta 10 mg/ml Infusionslösung
Spain:Lacosamida Vivanta10 mg/ml solution for infusion EFG
Netherlands:Lacosamide Vivanta 10 mg/ml, oplossing voor infusie
France:Lacosamide Vivanta 10 mg/ml solution for perfusion
Italy:Lacosamide Vivanta
Norway:Lacosamide Vivanta
Denmark:Lacosamide “Vivanta”
Finland:Lacosamide Vivanta 10 mg/ml infusion solution, liquid
Sweden:Lacosamide Vivanta 10 mg/ml infusion fluid, solution
Last review date of this leaflet:June 2023
More detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
This information is intended solely for doctors or healthcare professionals:
Each vial of Lacosamida Vivanta infusion solution should be used only once (single use). Unused solution should be discarded (see section 3).
Lacosamida Vivanta infusion solution can be administered without additional dilution, or it can be diluted with the following solutions: sodium chloride 9 mg/ml (0.9%), glucose 50 mg/ml (5%) or Ringer lactate solution.
From a microbiological point of view, the medication should be used immediately. If not used immediately, storage times in use and pre-use conditions are the responsibility of the user and should not exceed 24 hours at a temperature of between 2 and 8 °C, unless the dilution has taken place in validated and aseptic controlled conditions.
Chemical and physical stability in use has been demonstrated for 24 hours at temperatures up to 25 °Cfor medications mixed with these diluents and stored in glass or PVC bags.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.